Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
**Telephone:** +1-925-399-1568
**E-mail:** bpgoffice@wjgnet.com
**https**://www.wjgnet.com

# PEER-REVIEW REPORT

**Name of journal:** *World Journal of Diabetes*

**Manuscript NO:** 82680

**Title:** Fixed-ratio combinations of basal insulin and glucagon-like peptide-1 receptor agonists as a promising strategy for treating diabetes

**Provenance and peer review**: Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05309430
**Position:** Peer Reviewer
**Academic degree:** MD

**Professional title:** Doctor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** Japan

**Manuscript submission date:** 2022-12-28

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-12-28 12:06

**Reviewer performed review:** 2022-12-30 13:18

**Review time:** 2 Days and 1 Hour

| | |
|---|---|
| **Scientific quality** | [ ] Grade A: Excellent [ ] Grade B: Very good [Y] Grade C: Good<br>[ ] Grade D: Fair [ ] Grade E: Do not publish |
| **Novelty of this manuscript** | [ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair<br>[ ] Grade D: No novelty |
| **Creativity or innovation of this manuscript** | [ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair<br>[ ] Grade D: No creativity or innovation |

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
**Telephone:** +1-925-399-1568
**E-mail:** bpgoffice@wjgnet.com
**https**://www.wjgnet.com

| | |
|---|---|
| **Scientific significance of the conclusion in this manuscript** | [ ] Grade A: Excellent [ Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No scientific significance |
| **Language quality** | [ ] Grade A: Priority publishing [ Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection |
| **Conclusion** | [ Y] Accept (High priority) [ ] Accept (General priority) [ ] Minor revision [ ] Major revision [ ] Rejection |
| **Re-review** | [ ] Yes [ Y] No |
| **Peer-reviewer statements** | Peer-Review: [ Y] Anonymous [ ] Onymous |
| | Conflicts-of-Interest: [ ] Yes [ Y] No |

## SPECIFIC COMMENTS TO AUTHORS

This paper has scientific reference value for the clinical treatment of type 2 diabetes.

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
**Telephone:** +1-925-399-1568
**E-mail:** bpgoffice@wjgnet.com
**https**://www.wjgnet.com

# PEER-REVIEW REPORT

**Name of journal:** *World Journal of Diabetes*

**Manuscript NO:** 82680

**Title:** Fixed-ratio combinations of basal insulin and glucagon-like peptide-1 receptor agonists as a promising strategy for treating diabetes

**Provenance and peer review**: Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 03302550
**Position:** Peer Reviewer
**Academic degree:** PhD

**Professional title:** Professor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** Japan

**Manuscript submission date:** 2022-12-28

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2023-01-02 01:41

**Reviewer performed review:** 2023-01-02 02:22

**Review time:** 1 Hour

| | |
|---|---|
| **Scientific quality** | [ ] Grade A: Excellent [Y] Grade B: Very good [ ] Grade C: Good<br>[ ] Grade D: Fair [ ] Grade E: Do not publish |
| **Novelty of this manuscript** | [ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair<br>[ ] Grade D: No novelty |
| **Creativity or innovation of this manuscript** | [ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair<br>[ ] Grade D: No creativity or innovation |

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
**Telephone:** +1-925-399-1568
**E-mail:** bpgoffice@wjgnet.com
**https**://www.wjgnet.com

| | |
|---|---|
| **Scientific significance of the conclusion in this manuscript** | [ ] Grade A: Excellent [ Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No scientific significance |
| **Language quality** | [ ] Grade A: Priority publishing [ Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection |
| **Conclusion** | [ ] Accept (High priority) [ Y] Accept (General priority) [ ] Minor revision [ ] Major revision [ ] Rejection |
| **Re-review** | [ ] Yes [ Y] No |
| **Peer-reviewer statements** | Peer-Review: [ Y] Anonymous [ ] Onymous |
| | Conflicts-of-Interest: [ ] Yes [ Y] No |

**SPECIFIC COMMENTS TO AUTHORS**

This is a very practical summarize. Anti-diabetic medications are often required for people with uncontrolled T2D to achieve their glycemic targets. Currently, clinicians can recommend several therapeutic approaches. whether patients are treated with a single or multiple oral antidiabetic agents, they often require the addition of an injectable agent (insulin or a glucagon-like peptide-1 receptor agonist (GLP-1RA). In addition to single-agent injectable products, fixed-ratio combination (FRC) injections, comprising basal insulin and a GLP-1RA, have recently become available, and their efficacy for glycemic control has been demonstrated in previous phase II/III trials. Several authors have argued that they are useful based on the results of these clinical trials, although real-world clinical evidence regarding their utility is limited. In this review, they discuss the utility of and clinical outcomes associated with the use of such FRCs in people with T2D. FRCs comprising basal insulin and a GLP-1RA have the potential to be such a "well-balanced" therapy. It is suggested that the author can add some contents of economic valence ratio. In addition, for a newly diagnosed diabetes patient, author can add whether to recommend FRCs or choose oral medicine?

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
**Telephone:** +1-925-399-1568
**E-mail:** bpgoffice@wjgnet.com
**https**://www.wjgnet.com

# PEER-REVIEW REPORT

**Name of journal:** *World Journal of Diabetes*

**Manuscript NO:** 82680

**Title:** Fixed-ratio combinations of basal insulin and glucagon-like peptide-1 receptor agonists as a promising strategy for treating diabetes

**Provenance and peer review**: Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 03928598
**Position:** Peer Reviewer
**Academic degree:** MD

**Professional title:** Doctor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** Japan

**Manuscript submission date:** 2022-12-28

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2023-01-02 02:57

**Reviewer performed review:** 2023-01-03 12:29

**Review time:** 1 Day and 9 Hours

| | |
|---|---|
| **Scientific quality** | [ Y] Grade A: Excellent [ ] Grade B: Very good [ ] Grade C: Good<br>[ ] Grade D: Fair [ ] Grade E: Do not publish |
| **Novelty of this manuscript** | [ Y] Grade A: Excellent [ ] Grade B: Good [ ] Grade C: Fair<br>[ ] Grade D: No novelty |
| **Creativity or innovation of this manuscript** | [ ] Grade A: Excellent [ Y] Grade B: Good [ ] Grade C: Fair<br>[ ] Grade D: No creativity or innovation |

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
**Telephone:** +1-925-399-1568
**E-mail:** bpgoffice@wjgnet.com
**https**://www.wjgnet.com

| | |
|---|---|
| **Scientific significance of the conclusion in this manuscript** | [ ] Grade A: Excellent [ Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No scientific significance |
| **Language quality** | [ Y] Grade A: Priority publishing [ ] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection |
| **Conclusion** | [ ] Accept (High priority) [ Y] Accept (General priority) [ ] Minor revision [ ] Major revision [ ] Rejection |
| **Re-review** | [ Y] Yes [ ] No |
| **Peer-reviewer statements** | Peer-Review: [ Y] Anonymous [ ] Onymous |
| | Conflicts-of-Interest: [ ] Yes [ Y] No |

**SPECIFIC COMMENTS TO AUTHORS**

This paper is a good summary of the current status of clinical use of insulin and glucagon in fixed ratios for the treatment of T2DM, and the topic is novel.